MedTrace Logo

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

NCT02683200 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-02-21

No results posted yet for this study

Summary

This pilot clinical trial studies magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy (SBRT) in treating patients with liver metastases or liver cancer. SBRT is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Combining MRI with SBRT may help doctors to highlight the tissues surrounding the tumor better.

Conditions

  • Adult Hepatocellular Carcinoma
  • Metastatic Malignant Neoplasm in the Liver

Interventions

RADIATION

Image-Guided Adaptive Radiation Therapy

Undergo MRI-guided Tri-60Co teletherapy SBRT

RADIATION

Stereotactic Body Radiation Therapy

Undergo MRI-guided Tri-60Co teletherapy SBRT

Sponsors & Collaborators

Principal Investigators

  • Ann Raldow, MD · UCLA / Jonsson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-03
Primary Completion
2022-01-01
Completion
2022-01-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02683200 on ClinicalTrials.gov